Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALFLU: High-Dose vs Standard-Dose Influenza Vaccine in Older Adults
NCT06141655Phase 4Completed
- Start
- Oct 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of influenza vaccine (quadrivalent, high-dose) in influenza (2 arms). Primary endpoint: Occurrence of a hospitalization due to influenza or pneumonia. Started Oct 2023; status: completed.
02
Drugs
influenza vaccine (quadrivalent, high-dose)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06141655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141655.